Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment
- PMID: 33628020
- PMCID: PMC7898203
- DOI: 10.2147/IJN.S283416
Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment
Abstract
Diabetes mellitus is a major threat to human health. Both its incidence and prevalence have been rising steadily over the past few decades. Biomacromolecular agents such as insulin and glucagon-like peptide 1 receptor agonists are commonly used hypoglycemic drugs that play important roles in the treatment of diabetes. However, their traditional frequent administration may cause numerous side effects, such as pain, infection or local tissue necrosis. To address these issues, many novel subcutaneous delivery systems have been developed in recent years. In this review, we survey recent developments in subcutaneous delivery systems of biomacromolecular hypoglycemic drugs, including sustained-release delivery systems and stimuli-responsive delivery systems, and summarize the advantages and limitations of these systems. Future opportunities and challenges are discussed as well.
Keywords: diabetes mellitus; glucagon-like peptide 1 receptor agonists; insulin; stimuli-responsive; subcutaneous injection; sustained-release.
© 2021 Li et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures









Similar articles
-
Microparticles, microcapsules and microspheres: A review of recent developments and prospects for oral delivery of insulin.Int J Pharm. 2018 Feb 15;537(1-2):223-244. doi: 10.1016/j.ijpharm.2017.12.036. Epub 2017 Dec 26. Int J Pharm. 2018. PMID: 29288095 Review.
-
Endless Pursuit: Evolution of Insulin Administration.Curr Pharm Biotechnol. 2018;19(9):742-753. doi: 10.2174/1389201019666180918112922. Curr Pharm Biotechnol. 2018. PMID: 30227816 Review.
-
Nanoparticulate-based drug delivery systems for small molecule anti-diabetic drugs: An emerging paradigm for effective therapy.Acta Biomater. 2018 Nov;81:20-42. doi: 10.1016/j.actbio.2018.09.049. Epub 2018 Sep 28. Acta Biomater. 2018. PMID: 30268916 Review.
-
Novel strategies to oral delivery of insulin: Current progress of nanocarriers for diabetes management.Drug Dev Res. 2022 Apr;83(2):301-316. doi: 10.1002/ddr.21903. Epub 2021 Dec 2. Drug Dev Res. 2022. PMID: 34859477 Review.
-
A Review on Bioengineering Approaches to Insulin Delivery: A Pharmaceutical and Engineering Perspective.Macromol Biosci. 2019 Apr;19(4):e1800458. doi: 10.1002/mabi.201800458. Epub 2019 Jan 6. Macromol Biosci. 2019. PMID: 30614193 Review.
Cited by
-
Emerging Fabrication Strategies of Hydrogels and Its Applications.Gels. 2022 Mar 24;8(4):205. doi: 10.3390/gels8040205. Gels. 2022. PMID: 35448106 Free PMC article. Review.
-
Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies.Int J Mol Sci. 2025 Feb 28;26(5):2196. doi: 10.3390/ijms26052196. Int J Mol Sci. 2025. PMID: 40076813 Free PMC article. Review.
-
Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics.Adv Sci (Weinh). 2023 Mar;10(7):e2205389. doi: 10.1002/advs.202205389. Epub 2023 Jan 15. Adv Sci (Weinh). 2023. PMID: 36642846 Free PMC article.
-
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.Signal Transduct Target Ther. 2025 Mar 5;10(1):74. doi: 10.1038/s41392-024-02107-5. Signal Transduct Target Ther. 2025. PMID: 40038239 Free PMC article. Review.
-
Exploiting the potential of in situ forming liquid crystals: development and in vitro performance of long-acting depots for peptide drug thymosin alpha 1 subcutaneous administration.Drug Deliv. 2025 Dec;32(1):2460708. doi: 10.1080/10717544.2025.2460708. Epub 2025 Mar 11. Drug Deliv. 2025. PMID: 40066714 Free PMC article.
References
-
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 executive summary. Endocr Pract. 2019;25(1):69–100. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous